Investigator propose the implementation of circulating biomarker monitoring, focusing on molecules related to the progression of gastric atrophy and/or associated with gastric cancer. Monitoring these biomarkers will provide gastroenterologists with timely information on individuals at risk and, if values worsen during follow-up, will alert physicians observing these patients to evaluate them. This monitoring will be offered to individuals who contact the IBO (Immunopatologia e Biomarcatori Oncologici) Unit at CRO (Centro di Riferimento Oncologico) in Aviano requesting an assessment of gastric function through pepsinogen and G17 gastrin level testing. Monitoring these biomarkers will provide a dynamic analysis of patients' gastric status, allowing for timely intervention in case of deviations from normal values. This proactive approach is important for the preventive management of gastric diseases, particularly for the diagnosis and monitoring of gastric atrophy and gastric cancer. The IBO unit of the CRO in Aviano, together with the pathological anatomy and clinical units of gastroenterology, medical oncology, and surgery, will play a role in coordinating and implementing this monitoring program, thus contributing to the promotion of gastric health and the prevention of associated diseases.
Study Type
OBSERVATIONAL
Enrollment
192
Centro di Riferimento Oncologico (CRO) di aviano-IRCCS
Aviano, Pordenone, Italy
RECRUITINGEvaluate the association between the levels of selected biomarkers and the diagnosis obtained after endoscopic examination and histological evaluation of the biopsies taken.
The mean value of biomarkers level in positive and negative biopsy will be evaluated
Time frame: 36 months
Evaluate the prognostic potential of baseline levels of the biomarkers analyzed
Mean difference of biomarkers between responders and non responders
Time frame: 36 months
Identify biomarkers with the best relation with more advanced pre-neoplastic conditions and with neoplasia.
Mean difference of biomarkers level in subgroups of patients with the condition under investigation
Time frame: 36 months
Compare the predictive accuracy of risk between the DSCb test and the DSCb test with the addition of the best-performing biomarker
Accuracy will be calculated as number of patients correctly classified over the total number of patients.
Time frame: 36 months
Monitor test values during follow-up in subjects classified as high risk to assess the possible progression of the pre-neoplastic lesion
Likelihood ratio of the two tests will be reported
Time frame: 36 months
Monitor test values during follow-up in subjects with neoplasia to assess the potential of the test in therapeutic response
Test will be compared by mean of ROC curve analysis
Time frame: 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.